CO7051010A2 - Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata - Google Patents

Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata

Info

Publication number
CO7051010A2
CO7051010A2 CO14187582A CO14187582A CO7051010A2 CO 7051010 A2 CO7051010 A2 CO 7051010A2 CO 14187582 A CO14187582 A CO 14187582A CO 14187582 A CO14187582 A CO 14187582A CO 7051010 A2 CO7051010 A2 CO 7051010A2
Authority
CO
Colombia
Prior art keywords
test
prostate cancer
expression profile
genetic expression
cancer prognosis
Prior art date
Application number
CO14187582A
Other languages
English (en)
Inventor
Steve Shak
Mark Lee
William Novotny
Tara Maddala
Michael Crager
Diana Cherbavaz
Robert Pelham
Carl L Millward
Dejan Knezevic
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of CO7051010A2 publication Critical patent/CO7051010A2/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Data Mining & Analysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

VER ANEXOS.
CO14187582A 2012-01-31 2014-08-27 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata CO7051010A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593106P 2012-01-31 2012-01-31
US201261672679P 2012-07-17 2012-07-17
US201261713734P 2012-10-15 2012-10-15

Publications (1)

Publication Number Publication Date
CO7051010A2 true CO7051010A2 (es) 2014-09-10

Family

ID=48870540

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14187582A CO7051010A2 (es) 2012-01-31 2014-08-27 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata

Country Status (14)

Country Link
US (3) US8725426B2 (es)
EP (3) EP3739595A3 (es)
JP (3) JP6351112B2 (es)
AU (3) AU2013215448B2 (es)
CA (1) CA2863040C (es)
CO (1) CO7051010A2 (es)
DK (1) DK3179393T3 (es)
ES (1) ES2812105T3 (es)
HK (1) HK1201881A1 (es)
IL (3) IL233709A (es)
MX (3) MX366164B (es)
NZ (2) NZ722902A (es)
SG (3) SG10201605210PA (es)
WO (1) WO2013116144A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605210PA (en) * 2012-01-31 2016-08-30 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
EP3084426B1 (en) * 2013-12-18 2020-04-15 Pacific Biosciences Of California, Inc. Iterative clustering of sequence reads for error correction
CN103695560B (zh) * 2014-01-09 2016-09-14 上海交通大学医学院附属瑞金医院 Ppp1r12a基因在结直肠癌化疗疗效判断和检测试剂盒中的应用
WO2015109234A1 (en) * 2014-01-16 2015-07-23 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence
US20170016903A1 (en) * 2014-02-28 2017-01-19 The Johns Hopkins University Genes encoding secreted proteins which identify clinically significant prostate cancer
JP7065609B6 (ja) 2014-10-24 2022-06-06 コーニンクレッカ フィリップス エヌ ヴェ 複数の細胞シグナル伝達経路活性を用いる治療応答の医学的予後及び予測
ES2838923T3 (es) 2014-10-24 2021-07-02 Koninklijke Philips Nv Pronóstico médico y predicción de la respuesta a tratamiento usando múltiples actividades de la ruta de señalización celular
CA2965442A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Assessment of tgf-b cellular signaling pathway activity using mathematical modelling of target gene expression
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
EP3303616B1 (en) * 2015-05-29 2021-01-06 Koninklijke Philips N.V. Methods of prostate cancer prognosis
BR112017025430B1 (pt) * 2015-05-29 2024-04-30 Koninklijke Philips N.V. Método, uso de um produto, produto de programa de computador e sistema
US20180188258A1 (en) * 2015-07-01 2018-07-05 Keio University Marker for heterogeneity of cancer tissue, and use thereof
ES2861400T3 (es) 2015-08-14 2021-10-06 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de NFkB usando modelos matemáticos de la expresión de genes diana
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
AU2017209307B2 (en) * 2016-01-20 2023-06-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
ES2688213T3 (es) * 2016-07-15 2018-10-31 Proteomedix Ag Método para detectar proteínas en muestras humanas y usos de dichos métodos
WO2018039490A1 (en) 2016-08-24 2018-03-01 Genomedx Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11586674B2 (en) * 2016-12-28 2023-02-21 Khalifa University of Science and Technology Methods and systems for searching
EP3580357B1 (en) * 2017-02-13 2022-04-27 Genomic Health, Inc. Algorithms and methods for assessing late clinical endpoints in prostate cancer
CA3055925A1 (en) * 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3701532A1 (en) * 2017-10-27 2020-09-02 King Abdullah University Of Science And Technology A graph-based constant-column biclustering device and method for mining growth phenotype data
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502280A1 (en) * 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
EP3743533A1 (en) * 2018-01-25 2020-12-02 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
CN112673115A (zh) 2018-02-22 2021-04-16 液体活检研究有限责任公司 用于前列腺癌检测和治疗的方法
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN109001467A (zh) * 2018-07-20 2018-12-14 贵州省人民医院 一种用于前列腺癌的基因联合预后检测试剂及其制备方法
GB201816820D0 (en) * 2018-10-16 2018-11-28 Univ York Diagnostic method
WO2020092808A1 (en) 2018-10-31 2020-05-07 Regents Of The University Of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
WO2021030358A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
EP3901288A1 (en) * 2020-04-20 2021-10-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-gene expression assay for prostate carcinoma

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4158799A (en) 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
JP2003528564A (ja) 1998-06-06 2003-09-30 ジェノスティック ファーマ リミテッド 遺伝的プロファイリングに使用するプローブ
CA2702148C (en) 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
CN101643733A (zh) 2000-01-13 2010-02-10 杰南技术公司 新的stra6多肽
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
US20030087818A1 (en) 2001-02-02 2003-05-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CA2442820A1 (en) 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
AU2002357747A1 (en) 2001-12-10 2003-06-23 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
AU2003242820A1 (en) 2002-03-14 2003-09-22 Exonhit Therapeutics S.A. Variants of human kallikrein-2 and kallikrein-3 and uses thereof
AUPS187002A0 (en) 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
CA2498418A1 (en) 2002-09-10 2004-03-25 Guennadi V. Glinskii Gene segregation and biological sample classification methods
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
ES2651849T3 (es) 2003-07-10 2018-01-30 Genomic Health, Inc. Algoritmo del perfil de expresión y test para el pronóstico del cáncer
WO2005007830A2 (en) * 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20070105114A1 (en) 2003-07-29 2007-05-10 Martha Li Biomarkers of cyclin-dependent kinase modulation
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
ES2550614T3 (es) 2004-04-09 2015-11-11 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
CA2992180C (en) 2004-05-07 2021-02-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
AU2005249446A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of IMPDH pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
WO2006028655A2 (en) 2004-08-13 2006-03-16 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
WO2006110264A2 (en) 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
MX2007015416A (es) 2005-06-08 2008-02-19 Millennium Pharm Inc Metodos para la identificacion, evaluacion y tratamiento de pacientes con terapia contra cancer.
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1929306A4 (en) 2005-09-01 2009-11-11 Precision Therapeutics Inc CHEMOSENSIBLE ASSAYS, THE TUMOR CELLS WITH PERSISTENT PHENOTYPICAL CHARACTERISTICS
AU2006291054B2 (en) 2005-09-12 2011-10-13 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
CA2631236C (en) 2005-12-01 2019-10-29 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
MX2008008973A (es) 2006-01-11 2008-11-26 Genomic Health Inc Marcadores de expresion de genes para pronostico de cancer colorectal.
ES2300176B1 (es) 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US7914988B1 (en) * 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
WO2007149965A2 (en) 2006-06-22 2007-12-27 Wisconsin Alumni Research Foundation Stromal collagen in the diagnosis and characterization of breast cancer
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
JP2010509598A (ja) * 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション 前立腺癌バイオマーカーを検出するための方法およびキット
EP2140020A2 (en) 2007-03-15 2010-01-06 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8835480B2 (en) * 2007-04-23 2014-09-16 California Institute Of Technology Inhibitors for steroid response elements and related methods
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
AU2009253675A1 (en) * 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
EP2318543A2 (en) 2008-07-16 2011-05-11 Dana-Farber Cancer Institute Inc. Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
WO2010056993A2 (en) 2008-11-14 2010-05-20 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
EP2370813A4 (en) 2008-12-04 2012-05-23 Univ California MATERIALS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF PROSTATE CANCER
EP4328589A3 (en) 2009-01-07 2024-05-22 Myriad Genetics, Inc. Cancer biomarkers
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
US20100303795A1 (en) 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
US10095829B2 (en) 2009-07-08 2018-10-09 Worldwide Innovative Network Computer implemented methods of treating lung cancer
EP4350001A2 (en) * 2009-11-23 2024-04-10 Genomic Health, Inc. Methods to predict clinical outcome of cancer
NZ705645A (en) 2010-01-11 2016-05-27 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
DK3147373T3 (da) * 2010-07-27 2019-08-12 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer
SG10201605210PA (en) * 2012-01-31 2016-08-30 Genomic Health Inc Gene expression profile algorithm and test for determining prognosis of prostate cancer

Also Published As

Publication number Publication date
JP6908571B2 (ja) 2021-07-28
AU2018201688A1 (en) 2018-04-05
MX366164B (es) 2019-07-01
SG11201404390WA (en) 2014-08-28
IL233709A (en) 2017-09-28
NZ627887A (en) 2016-08-26
US11011252B1 (en) 2021-05-18
AU2018201688B2 (en) 2020-02-27
HK1201881A1 (en) 2015-09-11
JP2015511814A (ja) 2015-04-23
JP2017113008A (ja) 2017-06-29
JP6351112B2 (ja) 2018-07-04
MX2019007814A (es) 2019-09-05
EP3179393B1 (en) 2020-07-08
IL254255B (en) 2018-11-29
IL262648A (en) 2018-12-31
EP3179393A2 (en) 2017-06-14
IL233709A0 (en) 2014-09-30
IL262648B (en) 2020-07-30
EP2809812A4 (en) 2016-01-27
EP2809812A1 (en) 2014-12-10
US8725426B2 (en) 2014-05-13
EP3179393A3 (en) 2017-09-13
NZ722902A (en) 2017-12-22
CA2863040C (en) 2022-04-19
MX351626B (es) 2017-10-23
IL254255A0 (en) 2017-10-31
EP3739595A2 (en) 2020-11-18
AU2013215448B2 (en) 2018-01-04
AU2020202164A1 (en) 2020-04-16
CA2863040A1 (en) 2013-08-08
US20130196321A1 (en) 2013-08-01
MX2014009283A (es) 2014-09-11
ES2812105T3 (es) 2021-03-16
JP2019013255A (ja) 2019-01-31
SG10201605210PA (en) 2016-08-30
AU2013215448A1 (en) 2014-08-21
SG10201912312YA (en) 2020-02-27
EP3739595A3 (en) 2021-01-27
US20140303002A1 (en) 2014-10-09
DK3179393T3 (da) 2020-07-27
AU2020202164B2 (en) 2022-02-10
WO2013116144A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
CO7051010A2 (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata
CY1123716T1 (el) Αντι-ανδρογονα για τη θεραπεια μη μεταστατικου ευνουχοαντοχου καρκινου του προστατη
UY34822A (es) Composiciones y métodos para silenciar la expresión genética
CO7020893A2 (es) Conjunto de desgaste
CO7091177A2 (es) Inhibidores de la beta-secretasa
CO7151512A2 (es) Inhibidores del nampt
AU347955S (en) Audio system
AU341813S (en) Footwear
MX2021002014A (es) Metodo para determinar el riesgo de recidiva de cancer de mama.
HK1222888A1 (zh) 預測在淋巴結陽性早期乳癌復發風險的方法
AU343215S (en) Merchandiser
EP2885428A4 (en) GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER
WO2011153485A3 (en) Use of the sparc microenvironment signature in the treatment of cancer
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
AU344366S (en) Planting system
BR112015002145A2 (pt) pino intramedular
EP2882869A4 (en) PROSTATE CANCER GENE EXPRESSION PROFILES
CO7151534A2 (es) Endoglucanasas con propiedades mejoradas
CO7121349A2 (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
AU343344S (en) Mobile radiant heater
AU343346S (en) Mobile radiant heater
CA144820S (en) Building block
UY34069A (es) Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia
AU346735S (en) Signpost
AU346280S (en) Batten lug